A Study to Evaluate Available Treatment Information of Ponatinib, Bosutinib, Imatinib, Dasatinib and Nilotinib in Adults With Chronic Myeloid Leukemia

CompletedOBSERVATIONAL

Enrollment

1,769

Participants

Timeline

Start Date

October 6, 2021

Primary Completion Date

November 30, 2022

Study Completion Date

November 30, 2022

Conditions

Leukemia

Interventions

OTHER

No Intervention

As this is an observational study, no intervention will be administered in this study.

Trial Locations (1)

Takeda, Cambridge